{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:06:48Z","timestamp":1793232408991,"version":"4.5.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"1183","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. National Institutes of Health","doi-asserted-by":"crossref","award":["P30-CA014089"],"award-info":[{"award-number":["P30-CA014089"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Theranostics has its roots with the first radioiodine therapy for thyroid diseases in about 80\u2009years ago. More recently the field has experienced a remarkable renascence with the regulatory approval of paired imaging and radiopharmaceutical therapy agents in gastroenteropancreatic neuroendocrine tumours and metastatic castration-resistant prostate cancer that are now employed in routine clinical practice. The momentum is strong for identification and testing of new theranostic agents for use in various cancers and finding new clinical indications of the available agents. There are currently numerous preclinical, first-in-human studies, large-scale prospective registries, and clinical trials including randomized trials underway in cancer theranostics that target a variety of germane biological targets. The results of these investigations, if successful, will undoubtedly impact the future of cancer management which is anticipated to improve patient outcome. Multi-targeted theranostics may also provide opportunities for synergistic efficacy to tackle the inherent complexities driven by the heterogeneity of cancer. In this article, we review the currently active recruiting phase 2 and phase 3 clinical trials in cancer theranostics that are targeted to the prostate-specific membrane antigen, gastrin-releasing peptide receptor, and fibroblast activation protein, with the anticipated potential near-term (&amp;lt;5\u2009years) impact on clinical practice.<\/jats:p>","DOI":"10.1093\/bjr\/tqaf017","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T11:03:46Z","timestamp":1738062226000},"page":"1293-1298","source":"Crossref","is-referenced-by-count":4,"title":["Clinical trials in cancer theranostics with potential near-term impact on clinical practice"],"prefix":"10.1093","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9455-2484","authenticated-orcid":false,"given":"Hossein","family":"Jadvar","sequence":"first","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California , Los Angeles, CA 90033,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abtin","family":"Doroudinia","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California , Los Angeles, CA 90033,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S","family":"Conti","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California , Los Angeles, CA 90033,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M","family":"Colletti","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California , Los Angeles, CA 90033,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"issue":"2","key":"2026061713103640800_tqaf017-B1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1148\/radiol.2017170346","article-title":"Radiotheranostics in cancer diagnosis and management","volume":"286","author":"Jadvar","year":"2018","journal-title":"Radiology"},{"issue":"1","key":"2026061713103640800_tqaf017-B2","doi-asserted-by":"crossref","first-page":"10904","DOI":"10.1038\/s41467-024-55291-x","article-title":"The theranostic genome","volume":"15","author":"Xu","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"2026061713103640800_tqaf017-B3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2967\/jnumed.121.263262","article-title":"Appropriate use criteria for prostate-specific membrane antigen PET imaging","volume":"63","author":"Jadvar","year":"2022","journal-title":"J Nucl Med"},{"issue":"5","key":"2026061713103640800_tqaf017-B4","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"2026061713103640800_tqaf017-B5","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Leutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"2026061713103640800_tqaf017-B6","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.18632\/oncotarget.12240","article-title":"Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer","volume":"8","author":"Fendler","year":"2017","journal-title":"Oncotarget"},{"issue":"10276","key":"2026061713103640800_tqaf017-B7","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomized, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"2026061713103640800_tqaf017-B8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomized, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"issue":"8","key":"2026061713103640800_tqaf017-B9","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/14737140.2023.2223987","article-title":"What\u2019s to come in PSMA therapies and diagnostics: a summary of clinical trials involving PSMA radioligand-based therapeutic and\/or diagnostic approaches with active recruitment","volume":"23","author":"Dawson","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"2026061713103640800_tqaf017-B10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2967\/jnmt.122.264928","article-title":"Clinical trials of prostate-cancer membrane antigen radiopharmaceutical therapy","volume":"51","author":"Jadvar","year":"2023","journal-title":"J Nucl Med Technol"},{"issue":"1","key":"2026061713103640800_tqaf017-B11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/RLU.0000000000004919","article-title":"PSMA radioligand therapy in prostate cancer. Where are we and where are we heading?","volume":"49","author":"Almeida","year":"2024","journal-title":"Clin Nucl Med"},{"issue":"6_suppl","key":"2026061713103640800_tqaf017-B12","doi-asserted-by":"crossref","first-page":"TPS211","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS211","article-title":"PSMAFore: a phase 3 study to compare 177Lu- PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-na\u00efve patients with metastatic castration-resistant prostate cancer [abstract]","volume":"40","author":"Sartor","year":"2022","journal-title":"JCO"},{"issue":"suppl 2","key":"2026061713103640800_tqaf017-B13","first-page":"S1234","article-title":"Phase III trial of [177Lu]Lu-PSMA-617 in taxane-na\u00efve patients with metastatic castration resistant prostate cancer (PSMAfore) [abstract","volume":"34","author":"Sartor","year":"2023","journal-title":"]. Ann Oncol"},{"key":"2026061713103640800_tqaf017-B14","author":"Herrmann","year":"2024"},{"issue":"10459","key":"2026061713103640800_tqaf017-B15","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-na\u00efve patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomized, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"2026061713103640800_tqaf017-B16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s44276-024-00065-7","article-title":"Design issues with lutetium-177 PSMA-617 registration studies that bias the outcome of the experimental arm reflect an increasing misalignment of contemporary oncology trials with true patient benefit","volume":"2","author":"Schnog","year":"2024","journal-title":"BJC Rep"},{"issue":"15_suppl","key":"2026061713103640800_tqaf017-B17","doi-asserted-by":"crossref","first-page":"TPS5087","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5087","article-title":"Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH) [abstract]","volume":"39","author":"Chi","year":"2021","journal-title":"JCO"},{"key":"2026061713103640800_tqaf017-B18","doi-asserted-by":"crossref","first-page":"S1185","DOI":"10.1016\/j.annonc.2022.07.1886","article-title":"Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration-resistant prostate cancer (mCRPC): initial results from SPLASH","volume":"33","author":"Hansen","year":"2022","journal-title":"Ann Oncol"},{"key":"2026061713103640800_tqaf017-B19","author":"177Lu-PSMA-I&T for metastatic castration-resistant prostate cancer (ECLIPSE)","year":"2024"},{"key":"2026061713103640800_tqaf017-B20","author":"Press Release: Curium announces ECLIPSE trial has met primary endpoint, demonstrating a statistically and clinically meaningful benefit for patients with PSMA-positive metastatic castration resistant prostate cancer"},{"key":"2026061713103640800_tqaf017-B21","author":"Enzalutamide with Lu PSMA-617 versus enzalutamide alone in men with metastatic castration-resistant prostate cancer (ENZA-p)","year":"2024"},{"key":"2026061713103640800_tqaf017-B22","doi-asserted-by":"crossref","first-page":"S1325","DOI":"10.1016\/j.annonc.2023.10.086","article-title":"Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): a randomized, phase II trial: ENZA-p (ANZUP 1901)","volume":"34","author":"Emmett","year":"2023","journal-title":"Annal Oncol"},{"issue":"5","key":"2026061713103640800_tqaf017-B23","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicenter, randomized, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"2026061713103640800_tqaf017-B24","doi-asserted-by":"crossref","first-page":"TPS5110","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS5110","article-title":"CCTG PR21: a randomized phase II study of [177Lu]lu-PSMA-617 versus docetaxel in patients with metastatic castration-resistant and PSMA-positive disease (NCT04663997)","volume":"40","author":"Chi","year":"2022","journal-title":"JCO"},{"issue":"6_suppl","key":"2026061713103640800_tqaf017-B25","doi-asserted-by":"crossref","first-page":"TPS271","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS271","article-title":"EVOLUTION: phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (ANZUP 2001)","volume":"41","author":"Sandhu","year":"2023","journal-title":"JCO"},{"issue":"suppl 2","key":"2026061713103640800_tqaf017-B26","first-page":"241369","article-title":"Clinical trial protocol: a randomized phase 2 trial of FLEXible and extended dosing of 177Lu-PSMA-617 molecular radioligand therapy (FLEX-MRT)","volume":"65","author":"Holzgreve","year":"2024","journal-title":"J Nucl Med"},{"issue":"suppl","key":"2026061713103640800_tqaf017-B27","doi-asserted-by":"crossref","first-page":"TP210","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS210","article-title":"PSMAddition: a phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer [abstract]","volume":"40","author":"Sartor","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"2026061713103640800_tqaf017-B28","doi-asserted-by":"crossref","first-page":"TPS180","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS180","article-title":"UpfrontPSMA: a randomized phase II study of sequential 177Lu-PSMA-617 and docetaxel in metastatic hormone-na\u00efve prostate cancer (mHNPC) [abstract]","volume":"39","author":"Azad","year":"2021","journal-title":"JCO"},{"issue":"10","key":"2026061713103640800_tqaf017-B29","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicenter, open-label, randomized, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"2026061713103640800_tqaf017-B30","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.cpet.2024.03.004","article-title":"Gastrin releasing peptide receptors-targeted PET diagnostics and radionuclide therapy for prostate cancer management. Preclinical and clinical developments of the past 5 years","volume":"19","author":"Dalm","year":"2024","journal-title":"PET Clin"},{"issue":"4","key":"2026061713103640800_tqaf017-B31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11307-017-1151-1","article-title":"Prostate cancer theranostics targeting gastrin-releasing peptide receptors","volume":"20","author":"Baratto","year":"2018","journal-title":"Mol Imaging Biol"},{"key":"2026061713103640800_tqaf017-B32","author":"COMBAT Clinical Trial","year":"2024"},{"key":"2026061713103640800_tqaf017-B33","author":"NeoRay Clinical Trial","year":"2024"},{"issue":"7","key":"2026061713103640800_tqaf017-B34","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2967\/jnumed.123.265594","article-title":"Fibroblast activation protein inhibitor-based radionuclide therapies: current status and future directions","volume":"64","author":"Ora","year":"2023","journal-title":"J Nucl Med"},{"issue":"3","key":"2026061713103640800_tqaf017-B35","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.semnuclmed.2024.01.001","article-title":"PET imaging in sarcomas: a new frontier in nuclear medicine","volume":"54","author":"Giammarile","year":"2024","journal-title":"Semin Nucl Med"},{"issue":"4","key":"2026061713103640800_tqaf017-B36","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/RLU.0000000000004602","article-title":"Are we approaching a change in paradigm in PET\/CT imaging of the solid gastrointestinal (or digestive) tract tumors with the clinical application of FAPI imaging?","volume":"48","author":"Delgado Bolton","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"6","key":"2026061713103640800_tqaf017-B37","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"issue":"9","key":"2026061713103640800_tqaf017-B38","first-page":"1821","article-title":"Head-to-head comparison of FDG and radiolabeled FAPI PET: a systematic review of the literature","volume":"13","author":"Guglielmo","year":"2023","journal-title":"Life (Basel)"},{"issue":"3","key":"2026061713103640800_tqaf017-B39","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cpet.2023.02.010","article-title":"Current state of clinical trials and regulatory approvals with fibroblast activation protein targeting interventions","volume":"18","author":"Mosessian","year":"2023","journal-title":"PET Clin"},{"key":"2026061713103640800_tqaf017-B40","author":"Study of [18F]FAPI-74 PET in patients with gastrointestinal cancers (18F-FAPI-74 GI)","year":"2024"},{"key":"2026061713103640800_tqaf017-B41","author":"Study of [68Ga]FAPI-46 PET in patients with pancreatic ductal carcinoma (FAPI-46 PDAC)","year":"2024"},{"key":"2026061713103640800_tqaf017-B42","author":"An investigational scan (68Ga-FAPI-46 PET\/CT) for the imaging of cancer-associated fibroblasts in patients with localized pancreatic ductal adenocarcinoma","year":"2024"},{"key":"2026061713103640800_tqaf017-B43","year":"2024"},{"key":"2026061713103640800_tqaf017-B44"}],"container-title":["British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/advance-article-pdf\/doi\/10.1093\/bjr\/tqaf017\/61663061\/tqaf017.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/99\/1183\/1293\/61663061\/tqaf017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/99\/1183\/1293\/61663061\/tqaf017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:10:47Z","timestamp":1781716247000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/99\/1183\/1293\/7985571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":44,"journal-issue":{"issue":"1183","published-online":{"date-parts":[[2025,1,28]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bjr\/tqaf017","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2025,1,28]]}}}